Diabetes and Peptide Use

Diabetes and GH/IGF-1 Interaction

Diabetes matters most for peptides that act on growth hormone (GH), which works against insulin.

Physiological Interactions

In a 2-year trial in 65 healthy adults aged 60 to 81, MK-677 (25 mg daily) raised fasting glucose by about 5 mg/dL and lowered insulin sensitivity. In the 26-week tesamorelin trials on the Egrifta WR label, 5% of patients reached an HbA1c of 6.5% or higher, versus 1% on placebo. The blood work schedule overview covers these data.

Semaglutide and tirzepatide are different. As of October 2026, both are FDA-approved prescription medicines for type 2 diabetes (Ozempic, Mounjaro), not research peptides.

Type 1 Diabetes Considerations

Risk levels below are the site's reading of trial and label data, not guideline ratings.

Risk Assessment

Type 2 Diabetes Considerations

Risk Assessment

Relative vs. Absolute Contraindications

Research peptides have no label. The somatropin (Genotropin) label contraindicates growth hormone in active proliferative or severe non-proliferative diabetic retinopathy.

Absolute

Relative

What Labels and Clinicians Monitor

No label sets a schedule for research peptides. Approved drugs show what clinicians track:

The ADA defines prediabetes as fasting glucose of 100-125 mg/dL or HbA1c of 5.7-6.4%, and diabetes as 126 mg/dL or 6.5% and above.

Medication Considerations

Both GLP-1 labels say a prescriber may lower the insulin or sulfonylurea dose to reduce that risk.

Alternative Approaches

The Ozempic and Mounjaro labels describe both drugs as an adjunct to diet and exercise.

What We Still Don't Know

No trial has tested BPC-157 or TB-500 in people with diabetes, and the MK-677 and tesamorelin data come from older adults and people with HIV lipodystrophy. Other conditions are covered in the contraindicated conditions overview.